BE655653A - - Google Patents
Info
- Publication number
- BE655653A BE655653A BE655653DA BE655653A BE 655653 A BE655653 A BE 655653A BE 655653D A BE655653D A BE 655653DA BE 655653 A BE655653 A BE 655653A
- Authority
- BE
- Belgium
- Prior art keywords
- ulcers
- diphenylhydantoin
- sodium
- process according
- treatment
- Prior art date
Links
- 208000025865 Ulcer Diseases 0.000 claims description 23
- 231100000397 ulcer Toxicity 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims description 4
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 4
- JBSMSVZHETUQQA-UHFFFAOYSA-N 5,5-diphenylimidazolidine-2,4-dione;sodium Chemical compound [Na].N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 JBSMSVZHETUQQA-UHFFFAOYSA-N 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- -1 diaryl hydantoin Chemical compound 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012154 short term therapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32322363A | 1963-11-13 | 1963-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE655653A true BE655653A (enrdf_load_stackoverflow) | 1965-05-12 |
Family
ID=23258236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE655653D BE655653A (enrdf_load_stackoverflow) | 1963-11-13 | 1964-11-12 |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE655653A (enrdf_load_stackoverflow) |
-
1964
- 1964-11-12 BE BE655653D patent/BE655653A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002537252A (ja) | 心血管事象を予防するための必須脂肪酸 | |
| FR2480121A1 (fr) | Composition pharmaceutique de dextromethorphane permettant d'attenuer la douleur | |
| CN101897687B (zh) | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 | |
| LU82013A1 (fr) | Nouvelles poudres lyophilisees contenant un sel de l'acide thiazolidine-4-carboxylique et leur procede de preparation | |
| DE3785689T2 (de) | Verwendung von prostaglandin-biosynthese-hemmer. | |
| EP0219912B1 (en) | The use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders | |
| BE655653A (enrdf_load_stackoverflow) | ||
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| FR2686251A1 (fr) | Composition pour la cicatrisation d'une plaie. | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| FR2713487A1 (fr) | Solutions de type homéopathique contenant un acide nucléique utilisables notamment dans la prévention ou le traitement de maladies infectieuses ou de maladies impliquant le dysfonctionnement d'un gène. | |
| BE1009851A3 (fr) | Composition pharmaceutique pour le traitement des cephalees et son utilisation. | |
| JPWO2020234781A5 (enrdf_load_stackoverflow) | ||
| EP0758245B1 (fr) | Utilisation de la spiramycine dans des desordres gastrointestinaux dus a h. pyroli | |
| FR2709964A1 (fr) | Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès. | |
| US12029771B2 (en) | Neem for treatment of RLS | |
| FR2693106A1 (fr) | Association de trois principes actifs extraits du pentadiplandra brazzeana. | |
| EP1296667B1 (fr) | Composes pour la prevention et/ou le traitement des urticaires | |
| EP0303597B1 (fr) | Utilisation d'acide p-aminobenzöique pour la fabrication d'un médicament pour le traitement de photoallergies | |
| JP2023518430A (ja) | 感染症の治療におけるブシラミンの使用 | |
| FR2855056A1 (fr) | Medicament notamment pour le traitement de la drepanocytose ou du sida | |
| IL320111A (en) | Cnp compounds | |
| CA2027593C (fr) | Composition a activite anti-agregante plaquettaire utilisable en therapeutique | |
| AU2008241370B2 (en) | Essential oil of kunzea ambigua and methods of use | |
| Maxwell | BRIEF INSTRUCTIONS FOR THE TREATMENT OF LEPERS |